##plugins.themes.academic_pro.article.main##

Abstract

Bronchiectasis is characterized by a constant and abnormal expansion of the airways of the lungs (bronchi) and/or a violation of the tone of the muscle layer of the bronchial wall due to inflammation, sclerosis, dystrophy, hypoplasia. Bronchiectasis is a very common disease that is the main cause of respiratory problems. A deficiency in the host's immune response to bacterial infection is considered to be the main condition for the development of bronchiectasis. In addition, many patients have no identifiable cause and are defined as having an idiopathic disease. This can lead to the development of a chronic respiratory tract infection and subsequent inflammation. Patients tend to have persistent disease despite aggressive use of antibiotics and optimal sputum clearance techniques. New therapies based on the manipulation of the immune response are becoming available and offer significant promise for the treatment of this condition

Keywords

bronchiectasis respiratory infections inflammation

##plugins.themes.academic_pro.article.details##

How to Cite
Hikmatov Jasur Safarovich. (2023). Immunological Approaches to The Pathogenesis and Treatment of Bronchiectasis. Texas Journal of Medical Science, 21, 80–87. https://doi.org/10.62480/tjms.2023.vol21.pp80-87

References

  1. Ходош Э.М. Бронхоэктатическая болезнь: Учебное пособие для самостоятельной работы
  2. пульмонологов, торакальных хирургов, фтизиатров, терапевтов и врачей общей практики [Текст]
  3. / Э.М. Ходош. — Х., 2018. — 71 с.: ил.
  4. Weycker D., Hansen G. L., Seifer F. D. Prevalence and incidence of noncystic fibrosis bronchiectasis
  5. among US adults in 2013. Chronic Respiratory Disease. 2016;14(4):377–384.
  6. Polverino E., Cacheris W., Spencer C., Operschall E. In O'Donnell AE: Global burden of non-cystic
  7. fibrosis bronchiectasis: A simple empidemiologic analysis. 2012.
  8. Khikmatov, J. S., Khudaibergenov Sh. N., Khamdamov B. Z., Ismatov J. K. "Bronchiectasis (literature
  9. review)." Scientific progress 2.7 (2021): 94-108.
  10. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and Economic Burden of Bronchiectasis. Clinical
  11. Pulmonary Medicine. 2005;12(4):205-209
  12. Hikmatov J.S. "Bronchiectasis disease: etiology, pathogenesis, modern diagnosis and treatment."
  13. Новости образования: исследование в XXI веке 1.3 (2022): 1048-1064.
  14. Martínez-García M. Á., Soler-Catalunã J. J., Sanz Y. D., et al. Factors associated with bronchiectasis in
  15. patients with COPD. CHEST. 2011;140(5):1130–1137.
  16. King PT. The Role of the Immune Response in the Pathogenesis of Bronchiectasis. Biomed Res Int.
  17. ;2018:6802637.
  18. Redondo M., Keyt H., Dhar R., Chalmers J. D. Global impact of bronchiectasis and cystic fibrosis.
  19. Breathe. 2016;12(3):222–235.
  20. Quinti I., Soresina A., Spadaro G., et al. Long-term follow-up and outcome of a large cohort of patients
  21. with common variable immunodeficiency. Journal of Clinical Immunology. 2007;27(3):308–316.
  22. Pasteur M. C., Helliwell S. M., Houghton S. J., et al. An investigation into causative factors in patients
  23. with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2000;162(4):1277–
  24. Vendrell M., de Gracia J., Rodrigo M.-J., et al. Antibody production deficiency with normal IgG levels
  25. in bronchiectasis of unknown etiology. CHEST. 2005;127(1):197–204.
  26. Zimmer J., Andrès E., Donato L., Hanau D., Hentges F., de la Salle H. Clinical and immunological aspects
  27. of HLA class I deficiency. QJM: Monthly Journal of the Association of Physicians. 2005;98(10)
  28. Chalmers J. D., McHugh B. J., Doherty C., et al. Mannose-binding lectin deficiency and disease severity
  29. in non-cystic fibrosis bronchiectasis: a prospective study. The Lancet Respiratory Medicine.
  30. ;1(3):224–232.
  31. Paulson M. L., Freeman A. F., Holland S. M. Hyper IgE syndrome: An update on clinical aspects and the
  32. role of signal transducer and activator of transcription 3. Current Opinion in Allergy and Clinical
  33. Immunology. 2008;8(6):527–533.
  34. Kearney P. J., Kershaw C. R., Stevenson P. A. Bronchiectasis in acute leukaemia. British Medical Journal.
  35. ;2(6091):857–859.
  36. Knowles G. K., Stanhope R., Green M. Bronchiectasis complicating chronic lymphatic leukaemia with
  37. hypogammaglobulinaemia. Thorax. 1980;35(3):217–218.
  38. Chen L. W., McShane P. J., Karkowsky W., et al. De Novo Development of Bronchiectasis in Patients
  39. With Hematologic Malignancy. CHEST. 2017;152(3):683–685.
  40. Basnayake T. L., Morgan L. C., Chang A. B. The global burden of respiratory infections in indigenous
  41. children and adults: A review. Respirology. 2017;22(8):1518–1528.
  42. Chang A. B., Marsh R. L., Upham J. W., et al. Toward making inroads in reducing the disparity of lung
  43. health in Australian indigenous and new zealand maori children. FrontPediatr. 2015;3:9
  44. Singleton R., Morris A., Redding G., et al. Lewis C: Bronchiectasis in Alaska Native children: causes and
  45. clinical courses. PediatrPulmonol. 2000;29(3):182–187.
  46. Watt A. P., Brown V., Courtney J., et al. Neutrophil apoptosis, proinflammatory mediators and cell counts
  47. in bronchiectasis. Thorax. 2004;59(3):231–236.
  48. Whitters D., Stockley R. Immunity and bacterial colonisation in bronchiectasis. Thorax.
  49. ;67(11):1006–1013.
  50. Simpson J. L., Grissell T. V., Douwes J., Scott R. J., Boyle M. J., Gibson P. G. Innate immune activation
  51. in neutrophilic asthma and bronchiectasis. Thorax. 2007;62(3):211–218.
  52. Salvator H., Mahlaoui N., Catherinot E., et al. Pulmonary manifestations in adult patients with chronic
  53. granulomatous disease. European Respiratory Journal. 2015;45(6):1613–1623.
  54. Ho J. C., Tipoe G., Zheng L., et al. In vitro study of regulation of IL-6 production in bronchiectasis.
  55. Respiratory Medicine. 2004;98(4):334–341.